Experience Matters
Providing expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia.
Welcome to Lucid Health Consulting
With over 30 years of Health Economics, Pricing & Reimbursement, Strategic Market Access and Health Technology Assessment experience, we have helped many organisations navigate the complexities of the Australian regulatory environment and achieve market access.
We have a proven track record of enabling companies and organisations to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.
Let us show you how our strategic approach and team experience can help you achieve market access in Australia.
How we can help your business?
What’s New
Read our articles, find out about our upcoming webinars and speaking engagements for the latest industry insights.
ISPOR Europe 2022, 6 – 9 November with Poster
The ISPOR Europe 2022 Global Conference for Health Economics and Outcomes Research (HEOR) was held this year on 6-9 November, in-person in Vienna and virtually for discussion and dissemination of the latest trends in healthcare. This year’s conference theme was:...
8th Annual Drugs & Devices Australia Webinar – Reimbursement Update 2022
Free Webinar: 8th Annual Drugs & Devices Australia – Reimbursement Update Please join us for this free webinar, hosted by George Papadopoulos, Partner & Director of Lucid Health Consulting and Sarah Griffin, Director of MedTechnique Consulting as they discuss...
Welcome Kathryn Williams Day to the Lucid Health Consulting team
We are thrilled to announce the addition of Kathryn Williams Day to the Lucid Health Consulting team as Senior Consultant, Regulatory Affairs. Katy brings extensive regulatory affairs experience, backed by training in clinical pharmacy and public health in both the...
What our clients are saying.
Lucid Health Consulting are providers of expert advice in health economics, pricing & reimbursement, market access and regulatory affairs in Australia. Enabling companies to optimise the entry of their pharmaceutical, biotech and medical devices into the Australian market.